Table 3. Clinical variables, glucose concentration and insulin parameters.

Variable		Baseline	Final	Change at 12 weeks relative to baseline	Treatment difference
		Mean±SD	Mean±SD	Adjusted least square mean [95%CI] (% change from baseline)	Adjusted least square mean [95%CI] (% difference from placebo)	P
Clinical Parameters
BMI (Kg/m2)	Placebo	27.97±8.661	26.72±3.76	-0.15 [-1.47; 1.16] (-0.54%)	-1.38 [-2.66; -0.10] (-5.5%)	0.034
	Intervention2	25.36±4.07	24.61±3.44	-1.53 [-2.96; -0.11] (-6.03%)
Weight (Kg)	Placebo	72.01 ± 15.51	72.01 ± 15.51	-0.14 [-1.00; 0.71] (-0.19%)	-0.93 [-1.74; -0.12] (-1.37%)	0.025
	Intervention	68.81 ± 12.62	66.92 ± 11.63	-1.08 [-1.99; -0.16] (-1.56%)
Waist circumference (cm)	Placebo	90.40±11.56	90.39±11.16	0.65[-1.36; 2.66] (0.72%)	0.30 [-1.62; 2.23] (0.39%)	0.754
	Intervention	86.20±11.76	86.24±10.76	0.96 [-1.17; 3.08] (1.11%)
Systolic blood pressure (mmHg)	Placebo	123.77±17.64	121.25±17.18
	Intervention	122.22±18.14	122.13±17.62
Diastolic blood pressure (mmHg)	Placebo	76.75±11.18	75.87±9.96
	Intervention	76.49±12.20	76.45±10.56
Heart rate (bpm)	Placebo	70.29±10.09	69.22±9.73
	Intervention	71.43±9.89	70.38±9.40
Glucose and Insulin
Glucose (mg/dL)	Placebo	92.77±10.30	92.78±10.50	-1.79 [-5.70; 2.12] (-1.93%)	-1.24 [-4.83; 2.35] (-1.42%)	0.493
	Intervention	90.58±9.27	90.27±10.12	-3.03 [-7.10; 1.03] (-3.35%)
Insulin (pmol/L)	Placebo	51.75±37.66	55.57±50.69	1.20 [-12.57; 14.97] (2.32%)	-6.53[-23.54; 10.47] (-11.72%)	0.447
	Intervention	56.68±63.68	50.46±35.11	-5.33 [-19.20; 8.55] (-9.40%)
HOMA-IR	Placebo	1.66±1.26	1.83±1.88	0.1 [-0.40; 0.59] (6.02%)	-0.30 [-0.91; 0.31] (-16.89%)	0.333
	Intervention	1.84±2.56	1.58±1.14	-0.20 [-0.70; 0.30] (-10.87%)

¹Data calculated on the intention-to-treat population (n = 51). Results from the ANCOVA model; ²Intervention  = AP  =  Armolipid Plus.